"Bristol-Myers Squibb announced in July that the Japanese Ministry of Health, Labor and Welfare approved daclatasvir, a potent, pan-genotypic NS5A replication complex inhibitor, and asunaprevir, an NS3/4A protease inhibitor, for patients with hepatitis C virus."
Great news for our Japanese members!
"Bristol-Myers Squibb announced in July that the Japanese Ministry of Health, Labor and Welfare approved daclatasvir, a potent, pan-genotypic NS5A replication complex inhibitor, and asunaprevir, an NS3/4A protease inhibitor, for patients with hepatitis C virus."
All Oral Tx reaches Japan
Japan Approves First All-Oral Hepatitis C Treatment, DaklinzaŽ
Tig